4,5-Diarylpyrrole Derivatives for CB1 Antagonist Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting CB1 cannabinoid receptors lack effective antagonistic properties for central and peripheral applications, particularly in therapeutic contexts such as psychiatric disorders, obesity, and pain management.
Innovation Solution
Development of 4,5-diaryl-2-aminomethylpyrrole derivatives with specific structural substitutions that act as antagonists for CB1 cannabinoid receptors, offering enhanced affinity and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds targeting CB1 cannabinoid receptors are used, then some therapeutic effects are achieved, but effective antagonistic properties for central and peripheral applications are lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of pyrrole derivatives, specifically at positions 4 and 5 of the pyrrole ring, to optimize CB1 receptor antagonistic activity. By varying substituents (R1-R6) and their configurations, the invention achieves compounds with enhanced in vitro affinity and antagonistic properties suitable for central and peripheral therapeutic applications.
2Reliability
If new pyrrole derivatives with enhanced affinity are developed, then therapeutic potential is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct functional segments: the core pyrrole ring, substituent groups at positions 4 and 5, and various R1-R6 side chains. This modular approach allows systematic optimization of each segment's contribution to CB1 receptor binding while maintaining overall structural manageability for synthesis and characterization.
Data Source
AI summary
The invention relates to compounds having formula (I), wherein: X represents a group (II); R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 represents a (C1-C12)alkyl group, a non-aromatic carbocyclic radical at (C3-C12) which may or may not be substituted, a methyl which is substituted by a non-aromatic carbocyclic radical at (C3-C12) which may or may not be substituted, a phenyl, benzyl, benzhydryl radical which may or may not be substituted, a substituted or non-substituted heterocyclic radical, a methyl substituted by a non-aromatic carbocyclic radical at (C3-C12) which may or may not be substituted; R3 represents a (C1-C5)alkyl or a (C3-C7) cycloalkyl; R4 represents a substituted or non-substituted phenyl; and R5 represents a substituted or non-substituted phenyl. The invention also relates to the preparation method thereof and the use of same in therapeutics.